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ABSTRACT
Objective: Lung fibrosis is a progressive respiratory disease with a high percentage of mortality. Till now, it had bad prognosis to conventional 
medications. This study was designed to evaluate the role of mesna, the well-known antioxidant agent, against pulmonary fibrosis.
Methods: Pulmonary fibrosis was induced by administration of amiodarone to Wistar rats. Lung indices, leukocytes count, oxidative stress markers, 
cytokines levels, and hydroxyproline contents, in addition to the histopathological tests, were done for control, amiodarone, and mesna plus 
amiodarone group.
Results: The elevated ratio of lung/body weight and total leukocytes count within bronchoalveolar lavage fluid for amiodarone rats was decline 
significantly when cotreated with mesna therapy. Furthermore, mesna significantly brought down the lipid peroxidation of amiodarone in lung tissue, 
represented by decreasing malondialdehyde level and increasing superoxide dismutase (SOD) and catalase activity. In addition, mesna diminished 
the profibrotic transforming growth factor-β1 level while elevated the antifibrotic interferon-γ level, and the high activity of the enzyme matrix 
metalloproteinase-7 was restored within mesna group. Meanwhile, mesna counteracts the increment of hydroxyproline contents and Ashcroft 
grading scale within amiodarone group. Histologically, critical improvement in the inflammatory cell penetration and alveolar septa was seen in the 
lung tissue of rats within mesna group, contrasted with those received just amiodarone. Trichome staining clarified that collagen deposition was 
notably diminished in the peri-alveolar and peri-bronchial area within mesna group. Moreover, mesna therapy downregulated SMAD3 protein level, 
which was overexpressed by amiodarone challenge.
Conclusion: This study gives evidence that mesna therapy may act as a protective agent against amiodarone-mediated pulmonary fibrosis.
Keywords: Pulmonary fibrosis, Amiodarone, Mesna.
INTRODUCTION
Pulmonary fibrosis is a disorder set apart by scarring in the lungs. 
Tissue somewhere down in the lungs turns out to be thick, hardened, 
and scarred, due to the aggregation of abundance connective tissue that 
is named “fibrosis.” As the lung tissue ends up scarred and thickening 
of its contents, oxygen supply in circulation diminished, which change a 
man’s capacity to inhale [1]. This disease is the most widely recognized of 
interstitial pulmonary disorders, and influences <5 million individuals 
in the world, with a mean survival rate of about 3 years. Despite the fact 
that exploration studies are continuous, there is no confirmation that 
any solution can altogether help with this disorder [2].
Management with amiodarone, a broad-spectrum antiarrhythmic 
drug, is related to lung damage bringing about deadly respiratory 
fibrosis [3]. The pathogenesis for amiodarone lung damage incorporates 
a direct injury to pulmonary tissue, extreme sensitivity response, lipid 
peroxidation, change of cell membrane features and stimulation of 
alveolar macrophages, ending with cytokine discharge, and release of 
other inflammatory mediators [4]. In spite of much data with respect 
to the component of amiodarone-initiated pulmonary fibrosis, treating 
this disease is much of the time troublesome, and measurement 
protocols to deal with stopping its progression still scanty [5].
Sodium 2-mercaptoethane sulfonate (mesna) is utilized medically 
to protect against hemorrhagic cystitis caused by chemotherapeutic 
agents such as ifosfamide and cyclophosphamide [6]. Mesna is a 
compound with small size and by uprightness of its sulfhydryl moiety, 
can possibly capturing the free radicals. At the point when given IV, 
mesna is metabolized in the circulation to its inert disulfide compound 
“demensia” which enter renal tubules and return back to its source 
“mesna” by glutathione (GSH) [7]. Due to the small mesna size, its 
capacity to take up by various tissues, and its free radical scavenging 
potential, it might be valuable for limiting tissue insult caused by 
different oxidant species [8].
Whereas many antioxidant agents had failed to ameliorated lung 
damage initiated by amiodarone therapy in animal models, the role of 
mesna in counteracting this insult has not yet been tested. This study 
was formed to detect the possible protective activity of mesna against 
lung fibrosis induced by amiodarone in Wistar rats.
METHODS
Experimental protocol
This research included 30 Wistar albino male rats weighing 
(180–220 g); they were gotten from the animal house, and the work was 
permitted by the ethics committee for animal experimentation in the 
College of Pharmacy/Mustansiriya University. The animals were kept 
up at controlled temperature (25±2°C) with light timetable 12–12 h 
light/dim cycles, enabled free access to water, and the nourished 
standard rodent chow included ad libitum. Mesna vial (1 g/10 ml) 
was acquired from Asta Pharma AG Germany, while amiodarone 
hydrochloride vial (150 mg/3 ml) from Sigma Chemicals, St Louis, MO, 
USA. All other chemicals and kits were of the highest purity.
Rats were randomized into three groups, each comprising 10 animals, 
as follow: Group 1 (n=10): On saline i.p for 3 weeks and considered 
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as negative control group; Group 2 (n=10): On saline i.p for 1 week 
before and 2 weeks with amiodarone (100 mg/kg/day i.p) and 
considered as positive control group; while Group 3 (n=10): On mesna 
(180 mg/kg/day, i.p.) for 1 week before and 2 weeks with amiodarone 
(100 mg/kg/day i.p) and considered as interventional treatment group.
Sampling of bronchoalveolar lavage (BAL)
Post-anesthesia, lung organs were set up for lavage by tubing the 
trachea with a limited needle joined by a syringe. This lavage was 
acquired by washing the chest 3 times with 3 ml normal saline through 
tracheal intubation. Cell suspensions were collected by centrifugation 
with low velocity. The hemocytometer was used for total cell counts, 
while cytospin preparations were used for differential cell counts by 
calculating cells colored with Giemsa stain [9]. The remaining of BAL 
fluid was used for additional tests.
Sampling of lung tissues
Toward the finish of study, cervical dislocation was used to sacrifice the 
animals under light ether anesthesia, where their relative lung weights 
and whole body weights were estimated to get lung indices by the 
formula: (weight of the lung)/(weight of the rat)×100. The lung tissues 
were isolated into two sections; one section was submerged in 0.9% 
normal saline to get the lung tissue homogenate which was set up in 
fitting homogenizing buffer solution and put away at −80°C as aliquots 
for additional tests. The remaining section was submerged in formalin 
solution (10%) for histopathological evaluation.
Biochemical measures in lung tissues and BAL fluid
Malondialdehyde (MDA) content was measured utilizing the 
thiobarbituric basic analysis as depicted by Ohkawa et al. [10], the level 
of superoxide dismutase (SOD) was estimated following the procedure 
of Kakkar et al. [11], while catalase level was surveyed by the technique 
for luck [12], where the breakdown of hydrogen peroxide is estimated. 
All these markers were detected in lung tissues.
Sandwich enzyme immunoassay (ELISA) technique was utilized 
for the measurement of interleukin-1β (IL-1β) as indicated by 
the directions given with Ray Biotech. [13]. Examinations of 
interferon-γ (IFN-γ) and transforming growth factor-β1 (TGF-β1) 
levels were additionally done with ELISA method using commercially 
available kits [14,15]. Rat IFN-γ kit (Bender Med Systems, Austria) 
and Invitrogen Multispecies TGF-β1 kit (BioSource, Invitrogen, 
USA) were utilized for assurance of these parameters. Matrix 
metalloproteinase-7 (MMP-7) levels were also estimated utilizing an 
ELISA kit (R and D Systems, Minneapolis, MN, USA) [16]. All these 
biomarkers were measured in BAL fluid.
Hydroxyproline contents of lung tissues were detected utilizing 
the Woessner’s principle which depends on spectrophotometric 
technique [17]. The tissue tests taken for hydroxyproline assurance 
were rinsed with saline and dried in a broiler set for 72 h at 100°C.
Histological examination and masson’s trichrome staining
After killing the rats, lung tissue was carefully dissected and fixed in 
10% (w/v) formaldehyde-phosphate buffered saline-buffered solution 
at 25°C, got dried out utilizing different ethanol concentrations and 
inserted in paraffin. The paraffin-installed tissues were sliced to 5 µm 
layers with a microtome (RM-2135, Leica Microsystems, Bensheim, 
Germany). To assess the histopathological alterations, the tissues were 
passing through hematoxylin and eosin staining, while to distinguish 
the extent of the collected collagen, staining was achieved with Masson’s 
trichrome method [18] by a professional pathologist.
Lung fibrosis grading
Each section was separately surveyed for the extent of interstitial 
fibrosis utilizing the semi-quantitative evaluating system depicted by 
Ashcroft et al. 1988 [19]. A score graduated from 0 (healthy tissues) 
to 8 (complete fibrosis) depended. Fibrosis score of these areas was 
calculated based on the mean score of all fields.
Immunohistochemical (IHC) assay
Tissue sections from every rat were inserted in paraffin. Paraffin 
sections with 5 µm-thick were collected for microscope examination. 
The tissues were blocked to be incubated with rat’s anti-SMAD3 
antibodies, biotinylated, and streptomycin-marked goat anti-rat 
antibody (Wuhan, China) to detect SMAD3 expression according to 
staining intensity [20].
Statistical analysis
The results of this study were displayed as means±standard error of 
mean. Statistical evaluation was performed by analysis of variance and 
post hoc test. Chi-square test was utilized for comparison of fractions. 
All examinations were made utilizing the SPSS program and p<0.05 was 
regarded as a significant difference.
RESULTS
Effects of mesna on body weight and relative lung weight
Compared to the control group, a significant decrease in the body 
weight was seen in the animals treated with amiodarone alone 
(p<0.05). Mesna expanded the body weight in rats on amiodarone, yet 
no significant difference was observed compared with amiodarone 
group. Meanwhile, the elevated ratio of lung weight/body weight (lung 
indices) for the amiodarone group significantly declined when treated 
with mesna (p<0.05) (Table 1).
Effects of mesna on BAL differential and total leukocytes count
In general, the recovered fraction of BAL fluid did not differ significantly 
among all studied groups (>85%). Table 2 showed that, when contrasted 
with control rats, amiodarone induced a significant increment in the 
BAL total leukocytes count (p<0.05). Regarding rats receiving mesna, 
total white blood cell count was an approach to that of control. 
Meanwhile, neutrophils within differential cells count were markedly 
Table 1: Effects of mesna on body weight and relative lung weight
Group n Initial body weight (g) Final body weight (g) Lung weight (mg) Lung indices (mg/kg)
Control 10 207.8±6.7 305.8±16.2 1,395.7±128.8 4,567.4±258.4
Amiodarone 10 207.0±8.8 284.7±14.5* 2,192.0±335.3* 7,715.3±1,105.0*
Amiodarone+Mesna 10 207.9±8.6 291.6±18.4 1,931.0±201.2*# 6,635.6±403.5*#
Values are expressed as mean±SEM. n=No. of rats per group. *p<0.05 versus control group, #p<0.05 versus amiodarone group
Table 2: Effects of mesna on BAL differential and total leukocytes count
Group n Total cells (×106 ml−1) Macrophage (%) Lymphocytes (%) Neutrophils (%) Eosinophil (%)
Control 10 0.55±0.056 93.55±1.2 3.9±1.7 3.8±0.7 1.3±0.1
Amiodarone 10 1.17±0.083* 62.7±9.7* 11.3±1.3* 23.6±8.5* 2.2±1.4
Amiodarone+Mesna 10 0.68±0.160 86.4±5.4 13.1±1.5# 1.9±0.8 0.5±0.6
Data presented as mean±SEM. BAL: Bronchoalveolar lavage, n: No. of rats per group. *p<0.05 versus other groups, #p<0.05 versus control group
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elevated in BAL fluid of those within the amiodarone group (p<0.05) 
and this increment was significantly counteracted by mesna (p<0.05).
Effects of mesna on oxidative stress markers of lung tissue
Lipid peroxidation
The consequence of this research demonstrated an elevation in the level 
of MDA in rats given amiodarone alone over that of control, which could 
be a sign of amiodarone- mediated tissue damage and harm (p<0.05). 
Meanwhile, mesna therapy significantly brought down the lipid 
peroxidation of amiodarone in lung tissues (p<0.05) by approaching 
the typical MDA concentration within the control group (Table 3).
SOD activity
The levels of SOD in the lung tissues of rats on just amiodarone shown 
to be decline significantly in contrast to the control rats (p<0.05). 
Administration of mesna observed to be fruitful in reestablishing the 
levels of this enzyme (Table 3).
Catalase activity
The activity of catalase in the tissue homogenate of amiodarone 
group was shown significantly lower than that of control (p<0.05). 
Mesna treatment, which enhanced catalase action of rats, exhibited an 
approximate enzyme activity with that of control (Table 3).
Effects of mesna on cytokines and MMP-7 levels of BAL fluid
Table 4 clarified that a significant increment in IL-1β level was observed 
in rats received amiodarone when contrasted with those got just saline 
(p˂0.05). However, those rats took mesna plus amiodarone showed 
no significant diminishing in IL-1β levels when contrasted with rats 
on amiodarone (p>0.05). Anyway, IL-1β levels in mesna rats exhibit 
a larger extent when contrasted with control, as shown in Table 4 
(p˂0.05).
As a profibrotic cytokine in BAL fluid, the TGF-β1 level was markedly 
elevated in the amiodarone group than control (p<0.05). Furthermore, 
amiodarone essentially diminished the BAL levels of the antifibrotic 
cytokine “IFN-γ” in contrast with the control rats (p<0.05) (Table 4). 
A significant decrement in TGF-β1 levels and increment in IFN-γ levels 
were detected for rats received mesna, in opposite to those on just 
amiodarone. In spite of these findings, a large difference continued in 
TGF-β1 and IFN-γ levels between rats taking mesna and those in the 
control group (p<0.05).
Outcomes also demonstrated a noteworthy increment in the levels 
of MMP-7 in BAL fluid on the light of amiodarone challenge (p<0.05). The 
level of this enzyme in rats that got mesna therapy was observed to be 
uniquely lower than rats on just amiodarone (p<0.05) and in the meantime, 
was identical to that within the control (p>0.05), as shown in Table 4.
Assessment of lung fibrosis
Pulmonary fibrosis was evaluated by estimating hydroxyproline 
amount as a marker of collagen deposition. Amiodarone created a 
marked increment in hydroxyproline contents when contrasted to 
the control (p<0.05). This augmentation was counteracted by mesna 
(p>0.05) (Table 5). Meanwhile, Ashcroft scale was indicated for grading 
lung fibrosis. This semi-quantitative analysis was normal for control 
rats. Administration of amiodarone revealed 3-folds increment in the 
pathology score when contrasted with the control group (p<0.05). 
Mesna therapy significantly counteracts the expansion in the score, as 
shown in table 5 (p>0.05).
Effects of mesna on the histological profile
Animals within amiodarone group demonstrated particular 
histopathological changes, represented by alveolar structure damage, 
inter-alveolar septal thickening, and extensive interstitial invasion by 
neutrophils and lymphocytes (Fig. 1b) compared with control group 
(Fig. 1a). Interestingly, the mesna medications gave assurance against 
these amiodarone histological abnormalities. Critical improvement in the 
inflammatory process and alveolar septal architecture was seen within 
mesna-lung tissues, contrasted with rats received just amiodarone (Fig. 1c).
Table 3: Effects of mesna on the levels of oxidative stress markers within lung tissue
Group n MDA (nmoles/mg tissue) SOD (U/mg tissue) CAT (µm H2O2 consumed/mg tissue/min)
Control 10 43.35±1.3 0.33±0.05 19.92±1.25
Amiodarone 10 63.60±1.9* 0.20±0.02* 11.65±0.79*
Amiodarone+Mesna 10 45.59±1.2 0.32±0.03 18.36±1.50
Values are expressed as mean±SEM. MDA: Malondialdehyde, SOD: Superoxide dismutase, CAT: Catalase, n: No. of rats per group. *p<0.05 versus other groups
Table 4: Effect of mesna on cytokines and MMP-7 levels of BAL fluid
Group n IL-1β (pg/gm) TGF-β1 (pg/ml) IFN-γ (pg/ml) MMP-7 (ng/mL)
Control 10 11.60±1.89 50.18±25.90 111.54±43.76 6.75±0.13
Amiodarone 10 48.23±5.60* 261.57±70.66* 10.71±3.40* 11.60±0.65*
Amiodarone+Mesna 10 38.54±4.11# 142.37±8.25# 34.53±2.32# 7.36±0.35 
Values are represented as mean±SEM. BAL: Bronchoalveolar lavage, IL-1β: Interleukin-1β, TGF-β1: Transforming growth factor-β1, IFN-γ: Interferon-γ, MMP-7: Matrix 
metalloproteinase-7, n=No. of rats per group. *p<0.05 versus other groups, #p<0.05 versus control group
Table 5: Hydroxyproline contents and grades of lung fibrosis
Group n Hydroxyproline (mg/g dried tissue) Grade of fibrosis (Ashcroft score)
Control 10 8.25±0.60 0.56±0.03
Amiodarone 10 13.66±0.84* 1.62±0.15*
Amiodarone+Mesna 10 6.41±0.86 0.52±0.06
Data presented as mean±SEM. n=No. of rats per group. *p<0.05 versus other groups
Fig. 1: Histological sections of lung tissues for the three 
studied groups. (a) Control group; (B) amiodarone group; and 
(C) amiodarone plus mesna group. Lung tissues were stained with 
H and E (amplification×400)
a b c
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Amount of collagen within the lungs considered as a marker of 
fibrosis after staining by Masson’s trichrome method. Not surprisingly, 
rats administered amiodarone showed an expanding of collagen 
accumulation, compacted alveoli, and substantial fibrotic regions, 
contrasted with rats within the control group (Fig. 2a and 2b). 
Meanwhile, collagen deposition was notably diminished in lung tissues 
of mesna group (Fig. 2c) when contrasted with rats administered just 
amiodarone.
Effects of mesna on SMAD3 expression within lung tissue
Under IHC staining, SMAD3 expression was identified within alveolar 
macrophages. After receiving amiodarone, rats markedly overexpressed 
SMAD3 (Fig. 3b), contrasted with control rats which exhibited weaker 
staining intensity (Fig. 3a). Meanwhile, with mesna group, fewer 
positively cellular staining was seen (Fig. 3c).
DISCUSSION
In the current study, a notable decrease in the body weight was 
reported with rats on just amiodarone, which could be ascribed to the 
pulmonary fibrosis [21]. After amiodarone administration, a marked 
increment in the relative lung weight was seen, contrasted with control 
rats. One previous study has also revealed a comparable increment 
in lung weight of rats challenged with pulmonary fibrosis [22]. This 
expansion in lung weight is an unmistakable sign of fibrosis that is 
described by progressive collagen accumulation, as clear from the 
expanded quantity of hydroxyproline showed in the lungs of rats on just 
amiodarone. Meanwhile, mesna administration was seen adequately 
protect from the lung fibrosis induced by amiodarone, so relative lung 
weight and body weight of rats with mesna were approximate with 
that of control.
Interstitial inflammation might be associated with amiodarone therapy, 
this represented by an increase in the leukocytes count. It’s revealed that 
the leukocytes assume a key part in the lung inflammatory process [23]. 
In the present study, a noteworthy increment in the total leukocytes 
count with a marked elevation in the lymphocytes, neutrophils, and 
eosinophils levels was apparent in the amiodarone group within BAL 
fluid. This finding was in accordance with previous reports studying 
drugs that initiate lung fibrosis [24,25]. The clear decline in the 
leukocytes level by mesna therapy shows considerable protection 
against lung inflammation caused by amiodarone, so documenting the 
anti-inflammatory effect of this substance against lung damage induced 
by these chemicals.
During amiodarone administration, it’s well documented that oxidative 
stress shared in the fibrotic accumulation within lung tissues. Once 
produced, reactive oxygen species (ROS) attacks specific targets such 
as DNA, lipid, protein, ending with cell membrane disruption, and lung 
injury [26]. In this study, we reported lipid peroxidation as represented 
by rising MDA activity within the amiodarone group. Furthermore, this 
group exhibited depletion in antioxidant activity, as evident by SOD 
and catalase levels reduction, in agreement with the findings of other 
studies [27,28]. However, it was observed that the extent of oxidative 
status approaches to that of control after administration of mesna, 
supporting its powerful antioxidant activities.
The process of oxidative stress may initiate lung injury that associated 
with amiodarone, which is upheld by the generation of superoxide 
anion through alveolar macrophages got from rats receiving 
amiodarone. Our results were in the line with that of Taylor et al., who 
revealed expanded oxidant generation in amiodarone group [29]. 
Along these lines, superoxide anion raised levels may reflect a 
respiratory reaction to an insult, and attenuating this oxidative stress 
by mesna could have restorative advantages for lung damage caused 
by amiodarone.
In a previous study, adding mesna to bleomycin inhibiting reduced GSH 
consumption and the subsequent lung harmful effects. The capacity 
of mesna to anticipate exhaustion of lung GSH pool proposed that its 
anti-fibrotic effect is attributed to its antioxidant activity. Mesna can 
spare GSH by going about as either stimulating its formation or by 
acting as ROS scavenger [30]. In accordance with our results, mesna 
had appeared to avoid damage after ischemia/reperfusion injury and 
its subsequent oxidative stress to renal tissue [6] and urotoxicity of 
ifosfamide [31], where it has been utilized as a valuable adjuvant to 
chemotherapeutic drugs.
Previous findings showed that activation of macrophages and release of 
inflammatory and cytotoxic mediators may drive amiodarone to induce 
lung fibrosis [4,5]. In the current study, the IL-1β level is elevated after 
receiving amiodarone, but not significantly reduced by mesna therapy. 
This pro-inflammatory cytokine is included in fibroblast deposition 
and acts potentially with TNF-α [32]. Hindrance of IL-1β was shown 
to inhibit pulmonary fibrosis attributed to bleomycin [33], while its 
upregulation initiates lung damage and fibrotic process in the late 
phases of the experimental models [34]. Furthermore, IL-1β and TNF-α 
can augment oxidant process in tissues [35], prompting generation 
of free radicals, which have been proposed to work as a cascade of 
signaling molecules [36]. In this manner, utilized of mesna in the present 
study, which associated with lowering the levels of these cytokines, was 
reported to inhibit oxidative stress.
Ongoing work exhibits that IL-1β initiates intense lung tissue 
infiltration ending with fibrosis, so it’s viewed as a valid mediator 
for pharmacologic intervention in this disorder [37]. The TNF-α was 
appeared to fortify IL-1 β release from macrophages, and, in turn, 
IL-1 β upregulates TNF-α and IL-6, where IL-6 additionally shown to be 
involved in the pathogenesis of lung fibrosis [38].
The TGF-β1 and IFN-γ are important players in the process of lung 
fibrosis. These mediators were utilized in numerous researches for 
fibrosis assessment [39]. In this study, an expansion was found in the 
levels of TGF-β1 and a reduction in levels of IFN-γ within amiodarone 
group; in accordance with the literature, while in mesna rats the 
creation of TGF-β in the lungs was fundamentally diminished. The task 
of TGF-β is basic in fibrosis as it converts fibroblast to myofibroblast 
and it’s the most powerful stimulator of extracellular matrix 
generation. Upregulation of this profibrotic factor produces significant 
fibrosis [40]. Several studies demonstrated that hindrance of TGF-β 
targeting molecule provides amelioration of the fibrotic process, 
Fig. 2: Histological sections of lung tissues for the three 
studied groups. (a) Control group; (b) amiodarone group; and 
(c) amiodarone plus mesna group. Lung tissues were stained by 
Masson’s trichrome method (amplification×200)
a b c
Fig. 3: Immunohistochemical staining for SMAD3 in lung tissues 
of the three studied groups. (a) Control group;  




Asian J Pharm Clin Res, Vol 12, Issue 1, 2019, 491-496
 Mshimesh 
recommending that medication focusing on the TGF-β could offer a 
helpful pharmacologic intervention for this disease [41,42].
IFN-γ can inhibit repairing of wounds and has been reported to limit 
lung fibrosis initiated by bleomycin model, where its level is inadequate. 
It restricts the proliferation of fibroblasts and production of collagen 
by restraining TGF-β upregulation [33]. Ziesche et al. demonstrated 
significant changes in the state of few subjects suffering fibrosis of lung 
tissues following IFN-γ treatment and recommended that this impact 
was attributed to the restraint of TGF-β1 [43]. In the current study, 
diminished levels of TGF-β1 and expanded levels of IFN-γ were seen in 
rats getting mesna versus those with just amiodarone.
Fibrosis can be defined as activation of extracellular matrix as a defense 
and repairing mechanism against tissue injury [44]. As has been 
accounted for by other studies, subjects with fibrosis of lung tissues 
demonstrate increased MMP-7 levels [45,46]. In addition, it has been 
found that rodents with MMP-7 knockout are shielded from drugs 
initiate lung damage, recommending the contribution of MMP-7 in the 
fibrotic process [47]. According to these observations, one can shed 
light on the possible role of this catalyst as a targeting enzyme of mesna. 
Without a doubt, our outcomes recommend a relationship of the MMP-7 
level with lung fibrosis by amiodarone. This elevation was shown to be 
counteracted by mesna therapy. Whether mesna is straightly focusing 
MMP-7, however, it requires to be evaluated.
In this study, mesna ameliorated amiodarone-associated pulmonary 
fibrosis, as clarified by the noteworthy decrease in collagen deposition 
estimated as hydroxyproline level, a marker of collagen overproduction. 
Previous observations found that hydroxyproline elevation associated 
with amiodarone was reduced by the utilization of substances such 
as curcumin [48] and melatonin [49]. In addition, with the present 
study, mesna therapy also inhibits structural deformities mediated 
by amiodarone as represented by the reduction of Ashcroft score, 
contrasted with rats receiving amiodarone alone.
Evaluation of fibrosis through biochemical detection of hydroxyproline 
is more predictable strategy than Ashcroft grading for looking at the 
impacts of antifibrotic drugs. This may be attributed to the fact that 
Ashcroft method had a large fluctuation due to many variables. For 
example, bleomycin challenge can cause fibrotic patches in all scores, 
in this manner it is sensitized to errors, and ten-folds magnifying for 
microscopic testing may cause assessment errors due to the more 
prominent nonuniformity of fibrotic alterations within microscopic 
sections [50].
Histological investigations were achieved to verify abnormalities 
of lung tissue in the amiodarone group and to confirm the proposed 
antifibrotic activity of mesna against these alterations. We found 
that lung damage mediated by amiodarone involved dual phases: 
(a) Inflammatory represented by epithelial injury associated with 
infiltration of leukocytes and (b) fibroproliferative represented by 
fibrosis due to overactivation of the extracellular matrix. These results 
were in accordance with another previous report [51].
The current study confirms that mesna exhibits a powerful amelioration 
of pulmonary histopathological changes. These observations consisted 
with that of Daba et al. and Zhao et al. where different free radical 
scavengers were administered to counteract fibrosis associated with 
bleomycin [52,53]. Here, in spite that amiodarone and bleomycin 
are two different agents with distinct pharmacological action and 
indications, the pathogenesis of lung fibrosis induced by them is similar 
in many points.
Staining with Masson’s trichrome additionally ensure fibrotic process 
mediated by amiodarone, which may be attributed to facilitating 
mobilization of collagen by collagenase enzyme “MMP-7.” Histological 
evaluation by this method confirmed that amiodarone markedly 
obstructs alveolar spaces due to collagen deposition, in accordance with 
other reports [54,55]. Meanwhile, significant histological improvement 
with reduction of collagen accumulation was reported with rats given 
mesna therapy.
IHC, SMAD3 in the current study was upregulated in amiodarone group, 
while administration of mesna markedly decreased expression of this 
protein. This finding was consistent with the fact that SMAD proteins, 
a group of transcription factors, acting as signaling molecules within 
downstream pathway of TGF-β1 receptors, where type I receptor 
stimulation leading to phosphorylation of SMAD2 and SMAD3 signaling 
pathway, ending with heteromerization with SMAD4 [56,57]. Deficiency 
of SMAD3 was also shown to ameliorate lung fibrosis mediated with 
bleomycin challenge in mice [58,59].
CONCLUSION
In this study, mesna seemed to have a protective role against 
amiodarone-mediated pulmonary fibrosis through inhibiting 
inflammatory status; augmenting antioxidant capacity; diminishing 
provocative cytokine levels; downregulating collagenase enzyme and 
preventing collagen deposition; and ending with improvement in the 
histologic morphology. In the future, mesna may be used clinically as 
an adjuvant agent with conventional therapy for this disorder. Further 
researches will be needed to know the mechanism of mesna in the 
pathogenesis of this disease.
ACKNOWLEDGMENTS
The author would like to thank Mustansiryiah University (www.
uomustansiriyah.edu.iq), Baghdad, Iraq, for its support in the present 
work. Special thanks to the professional pathologist Dr. Basim for 
helping in animal dosing and histological work, and to the immunologist 
Dr. Suzan for supporting in laboratory tests and statistical analysis.
AUTHORS’ CONTRIBUTIONS
Assistant Professor Dr. Bahir Abdul Razzaq (dr.bahirrazzq@
uomustansiriyah.edu.iq) has provided the design, protocol, and 
parameters suitable for conducting this experiment, in addition to 
the theoretical part (literature search, draft writing, and journal 
submission). Histological work (dissection, specimen collections, slide 
preparation, and reading) was achieved in a private laboratory.
CONFLICTS OF INTEREST
The author declared that there have no conflicts of interest.
REFERENCES
1. Kim DS. Acute exacerbations in patients with idiopathic pulmonary 
fibrosis. Respir Res 2013;14:86.
2. Maher TM. Idiopathic pulmonary fibrosis: Pathobiology of novel 
approaches to treatment. Clin Chest Med 2012;33:69-83.
3. Gill J, Heel RC, Fitton A. Amiodarone. An overview of its 
pharmacological properties, and review of its therapeutic use in cardiac 
arrhythmias. Drugs 1992;43:69-110.
4. Reinhart PG, Gairola CG. Amiodarone-induced pulmonary toxicity in 
Fischer rats: Release of tumor necrosis factor alpha and transforming 
growth factor beta by pulmonary alveolar macrophages. J Toxicol 
Environ Health 1997;52:353-65.
5. Chung WH, Bennett BM, Racz WJ, Brien JF, Massey TE. Induction 
of c-jun and TGF-beta 1 in Fischer 344 rats during amiodarone-
induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 
2001;281:L1180-8.
6. Mashiach E, Sela S, Weinstein T, Cohen HI, Shasha SM, Kristal B, 
et al. Mesna: A novel renoprotective antioxidant in ischaemic acute 
renal failure. Nephrol Dial Transplant 2001;16:542-51.
7. Gressier B, Lebegue N, Brunet C, Luyckx M, Dine T, Cazin M, et al. 
Scavenging of reactive oxygen species by letosteine, a molecule with 
two blocked-SH groups. Comparison with free-SH drugs. Pharm World 
Sci 1995;17:76-80.
8. Gressier B, Cabanis A, Lebegue S, Brunet C, Dine T, Luyckx M, 
et al. Decrease of hypochlorous acid and hydroxyl radical generated 
by stimulated human neutrophils: Comparison in vitro of some thiol-
496
Asian J Pharm Clin Res, Vol 12, Issue 1, 2019, 491-496
 Mshimesh 
containing drugs. Methods Find Exp Clin Pharmacol 1994;16:9-13.
9. Walters DM, Wills-Karp M, Mitzner W. Assessment of cellular profile 
and lung function with repeated bronchoalveolar lavage in individual 
mice. Physiol Genomics 2000;2:29-36.
10. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal 
tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
11. Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay 
of superoxide dismutase. Indian J Biochem Biophys 1984;21:130-2.
12. Luck H. A spectrophotometric method for the estimation of catalase. 
In: Bergmeyer HU, editor. Methods of Enzymatic Analysis. New York, 
USA: Academic Press; 1963. p. 886-7.
13.	 Grassi	 L,	 Roberge	 CJ,	 Frobert	 Y.	 Determination	 of	 IL-α,	 IL-β,	 and	
IL-2 in biological media using specific enzyme immunometric assays. 
Immunol Rev 1991;119:125-42.
14. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: 
An overview of signals, mechanisms and functions. J Leukoc Biol 
2004;75:163-89.
15. Kim JS, Yoon SS, Kim YH, Ryu JS. Serial measurement of interleukin-6, 
transforming growth factor-beta, and S-100 protein in patients with 
acute stroke. Stroke 1996;27:1553-7.
16. Parks WC, Wilson CL, López-Boado YS. Matrix metalloproteinases as 
modulators of inflammation and innate immunity. Nat Rev Immunol 
2004;4:617-29.
17. Edwards CA, O’Brien WD Jr. Modified assay for determination of 
hydroxyproline in a tissue hydrolyzate. Clin Chim Acta 1980;104:161-7.
18. Maynard JH. A trichrome stain in glycol methacrylate that works. Lab 
Med 1986;17:471.
19. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity 
of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41:467-70.
20. Bonniaud P, Margetts PJ, Ask K, Flanders K, Gauldie J, Kolb M, 
et al. TGF-beta and SMAD3 signaling link inflammation to chronic 
fibrogenesis. J Immunol 2005;175:5390-5.
21. Zhou XM, Zhang GC, Li JX, Hou J. Inhibitory effects of hu-qi-yin on 
the bleomycin-induced pulmonary fibrosis in rats. J Ethnopharmacol 
2007;111:255-64.
22. Soumyakrishnan S, Sudhandiran G. Daidzein attenuates inflammation 
and exhibits antifibrotic effect against bleomycin-induced pulmonary 
fibrosis in Wistar rats. Biomed Prev Nutr 2011;1 Suppl 4:236-44.
23. Wei X, Han J, Chen ZZ, Qi BW, Wang GC, Ma YH, et al. 
A phosphoinositide 3-kinase-gamma inhibitor, AS605240 prevents 
bleomycin-induced pulmonary fibrosis in rats. Biochem Biophys Res 
Commun 2010;397:311-7.
24. Sriram N, Kalayarasan S, Sudhandiran G. Epigallocatechin-3-gallate 
augments antioxidant activities and inhibits inflammation during 
bleomycin-induced experimental pulmonary fibrosis through nrf2-
keap1 signaling. Pulm Pharmacol Ther 2009;22:221-36.
25. Gong LK, Li XH, Wang H, Zhang L, Chen FP, Cai Y, et al. Effect of feitai 
on bleomycin-induced pulmonary fibrosis in rats. J Ethnopharmacol 
2005;96:537-44.
26. Liang X, Tian Q, Wei Z, Liu F, Chen J, Zhao Y, et al. Effect of feining 
on bleomycin-induced pulmonary injuries in rats. J Ethnopharmacol 
2011;134:971-6.
27. Grande NR, Peao MN, DeSa CM, Aguas AP. Lung fibrosis induced 
by bleomycin: Structural changes and overview of recent advances. 
Scanning Microscope 1998;12:487-94.
28. Sogut S, Ozyurt H, Armutcu F, Kart L, Iraz M, Akyol O, et al. 
Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats. Eur 
J Pharmacol 2004;494:213-20.
29. Taylor MD, Van Dyke K, Bowman LL, Miles PR, Hubbs AF, Mason RJ, 
et al. A characterization of amiodarone-induced pulmonary toxicity 
in F344 rats and identification of surfactant protein-D as a potential 
biomarker for the development of the toxicity. Toxicol Appl Pharmacol 
2000;167:182-90.
30. Lord-Fontaine S, Averill DA. Enhancement of cytotoxicity of hydrogen 
peroxide by hyperthermia in Chinese hamster ovary cells: Role of 
antioxidant defenses. Arch Biochem Biophys 1999;363:283-95.
31. Siu LL, Moore MJ. Use of mesna to prevent ifosfamide-induced 
urotoxicity. Support Care Cancer 1998;6:144-54.
32. Alabbassi MG. The possible protective effects of zileuton against 
pulmonary fibrosis induced by amiodarone in male rats. J Nat Sci Res 
2015;5 Suppl 2:88-92.
33. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 
signaling through the IL-13alpha2 receptor is involved in induction of 
TGF-beta1 production and fibrosis. Nat Med 2006;12:99-106.
34. Prechtl S, Roellinghoff M, Scheper R, Cole SP, Deeley RG, Lohoff M, 
et al. The multidrug resistance protein 1: A functionally important 
activation marker for murine th1 cells. J Immunol 2000;164:754-61.
35. Yang D, Elner SG, Bian ZM, Till GO, Petty HR, Elner VM, et al. 
Pro-inflammatory cytokines increase reactive oxygen species through 
mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res 
2007;85:462-72.
36. Lo YY, Wong JM, Cruz TF. Reactive oxygen species mediate 
cytokine activation of c-jun NH2-terminal kinases. J Biol Chem 
1996;271:15703-7.
37. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient 
expression of IL-1beta induces acute lung injury and chronic repair 
leading to pulmonary fibrosis. J Clin Invest 2001;107:1529-36.
38. Scheule RK, Perkins RC, Hamilton R, Holian A. Bleomycin stimulation 
of cytokine secretion by the human alveolar macrophage. Am J Physiol 
1992;262:L386-91.
39. Border WA, Noble NA. Transforming growth factor beta in tissue 
fibrosis. N Engl J Med 1994;331:1286-92.
40. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: 
The myofibroblast in focus. Chest 2007;132:1311-21.
41. Ask K, Bonniaud P, Maass K, Eickelberg O, Margetts PJ, Warburton D, 
et al. Progressive pulmonary fibrosis is mediated by TGF-beta isoform 
1 but not TGF-beta3. Int J Biochem Cell Biol 2008;40:484-95.
42. de Gouville AC, Huet S. Inhibition of ALK5 as a new approach to treat 
liver fibrotic diseases. Drug News Perspect 2006;19:85-90.
43. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary 
study of long-term treatment with interferon gamma-1b and low-dose 
prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J 
Med 1999;341:1264-9.
44. Yoon JS, Chae MK, Jang SY, Lee SY, Lee EJ. Antifibrotic effects of 
quercetin in primary orbital fibroblasts and orbital fat tissue cultures of 
graves’ orbitopathy. Invest Ophthalmol Vis Sci 2012;53:5921-9.
45. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, 
et al. MMP1 and MMP7 as potential peripheral blood biomarkers in 
idiopathic pulmonary fibrosis. PLoS Med 2008;5:e93.
46. Pardo A, Selman M. Role of matrix metaloproteases in idiopathic 
pulmonary fibrosis. Fibrogenesis Tissue Repair 2012;5:S9.
47. Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, et al. Gene 
expression analysis reveals matrilysin as a key regulator of pulmonary 
fibrosis in mice and humans. Proc Natl Acad Sci U S A 2002;99:6292-7.
48. Punithavathi D, Venkatesan N, Babu M. Curcumin inhibition of 
bleomycin-induced pulmonary fibrosis in rats. Br J Pharmacol 
2000;131:169-72.
49. Arslan SO, Zerin M, Vural H, Coskun A. The effect of melatonin 
on bleomycin-induced pulmonary fibrosis in rats. J Pineal Res 
2002;32:21-5.
50. Hübner RH, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, 
et al. Standardized quantification of pulmonary fibrosis in histological 
samples. Biotechniques 2008;44:507-11, 514-7.
51. Oury TD, Thakker K, Menache M, Chang LY, Crapo JD, Day BJ, 
et al. Attenuation of bleomycin-induced pulmonary fibrosis by a 
catalytic antioxidant metalloporphyrin. Am J Respir Cell Mol Biol 
2001;25:164-9.
52. Daba MH, Abdel-Aziz AA, Moustafa AM, Al-Majed AA, Al-
Shabanah OA, El-Kashef HA, et al. Effects of L-carnitine and ginkgo 
biloba extract (EG b 761) in experimental bleomycin-induced lung 
fibrosis. Pharmacol Res 2002;45:461-7.
53. Zhao J, Shi W, Wang YL, Chen H, Bringas P Jr., Datto MB, et al. 
SMAD3 deficiency attenuates bleomycin-induced pulmonary fibrosis 
in mice. Am J Physiol Lung Cell Mol Physiol 2002;282:L585-93.
54. Pardo A, Ruiz V, Arreola JL, Ramírez R, Cisneros-Lira J, Gaxiola M, 
et al. Bleomycin-induced pulmonary fibrosis is attenuated in gamma-
glutamyl transpeptidase-deficient mice. Am J Respir Crit Care Med 
2003;167:925-32.
55. Serrano-Mollar A, Closa D, Prats N, Blesa S, Martinez-Losa M, 
Cortijo J, et al. In vivo antioxidant treatment protects against bleomycin-
induced lung damage in rats. Br J Pharmacol 2003;138:1037-48.
56. Sushma RK, Sreedhara RP, Nayak JK, Hemalatha B, Keerthana P, 
Kumar MB. Biomechanical, biochemical and histological evidences for 
wound healing properties of Indian traditional medicines. Int J Pharm 
Pharm Sci 2015;7 Suppl 11:163-71.
57. Iman HH, Mohamed AE, Ghada MA, Walaa GH. Protective effects of 
Zingiber officinale against carbon tetrachloride induced liver fibrosis. 
Int J Pharm Pharm Sci 2016;8 Suppl 3:377-81.
58. Massaous J, Hata A. TGF-beta signalling through the SMAD pathway. 
Trends Cell Biol 1997;7:187-92.
59. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell 
membrane to nucleus through SMAD proteins. Nature 1997;390:465-71.
